Long-term outcomes with addition of inotuzumab ozogamicin to HCVAD and sequential blinatumomab in adults with newly diagnosed B-ALL.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Lewis Fady Nasr, Hannah Goulart, Nicholas James Short, Nitin Jain, Min Zhao, Tapan M. Kadia, Courtney Denton DiNardo, Naval Guastad Daver, Naveen Pemmaraju, Alessandra Ferrajoli, Alex Bataller, Fadi Haddad, Jayastu Senapati, Maria Hachem, Guillermo Garcia-Manero, Rebecca S. Garris, Farhad Ravandi-Kashani, Hagop M. Kantarjian, Elias Jabbour
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Pfizer
OpenAlex ID: W7162545473
Cites:
Cited by:
Related to: